Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Emory University
University of Florida
UNC Lineberger Comprehensive Cancer Center
Centre Leon Berard
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Amgen
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
British Columbia Cancer Agency
Centre Antoine Lacassagne
OHSU Knight Cancer Institute
Oncovir, Inc.
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)